Activity of tobramycin against cystic fibrosis isolates of Burkholderia cepacia complex grown as biofilms

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 348-355

  Kennedy, Sarah ^a   Beaudoin, Trevor ^a   Yau, Yvonne C W ^a   Caraher, Emma ^b   Zlosnik, James E A ^c   Speert, David P ^c   LiPuma, John J ^d   Tullis, Elizabeth ^e   Waters, Valerie ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIUM ISOLATE; BIOFILM; BURKHOLDERIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA DOLOSA; BURKHOLDERIA MULTIVORANS; BURKHOLDERIA VIETNAMIENSIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYSTIC FIBROSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPUTUM; CHEMISTRY; CHILD; DOSE RESPONSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOLOGY; SPECIES DIFFERENCE; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; BIOFILMS; BURKHOLDERIA; BURKHOLDERIA CEPACIA COMPLEX; CHILD; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; SPECIES SPECIFICITY; SPUTUM; TOBRAMYCIN;

EID: 84957875416     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02068-15     Document Type: Article

References (28)

1. Cystic Fibrosis Foundation. 2011. Patient data registry report. CF Foundation, Bethesda, MD.
2. Cystic Fibrosis Canada. 2013. Canadian patient data registry report. CF Canada, Toronto, Canada.
3. Corey M, Farewell V. 1996. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 143:1007-1017. http://dx.doi.org/10.1093/oxfordjournals.aje.a008664.
4. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, Morgan WM, Carson LA, Martone WJ, Jason JM. 1985. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 107:382-387. http://dx.doi.org/10.1016/S0022-3476(85)80511-4.
5. Waters V. 2012. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. Curr Pharm Des 18:696-725. http://dx.doi.org/10.2174/138161212799315939.
6. Schwab U, Abdullah LH, Perlmutt OS, Albert D, Davis CW, Arnold RR, Yankaskas JR, Gilligan P, Neubauer H, Randell SH, Boucher RC. 2014. Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus. Infect Immun 82:4729-4745. http://dx.doi.org/10.1128/IAI.01876-14.
7. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. 2011. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 10:54-61. http://dx.doi.org/10.1016/j.jcf.2010.10.003.
8. Ratjen A, Yau Y, Wettlaufer J, Matukas L, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V. 2015. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother 59:711-713. http://dx.doi.org/10.1128/AAC.04123-14.
9. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771-1776.
10. Tseng BS, Zhang W, Harrison JJ, Quach TP, Song JL, Penterman J, Singh PK, Chopp DL, Packman AI, Parsek MR. 2013. The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin. Environ Microbiol 15:2865-2878. http://dx.doi.org/10.1111/1462-2920.12155.
11. Clinical and Laboratories Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement M100-S22. CLSI, Wayne, PA.
12. Wu K, Yau YC, Matukas L, Waters V. 2013. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother 57:1546-1548. http://dx.doi.org/10.1128/AAC.02215-12.
13. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. 2007. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 42:307-313. http://dx.doi.org/10.1002/ppul.20594.
14. Bazzini S, Udine C, Sass A, Pasca MR, Longo F, Emiliani G, Fondi M, Perrin E, Decorosi F, Viti C, Giovannetti L, Leoni L, Fani R, Riccardi G, Mahenthiralingam E, Buroni S. 2011. Deciphering the role of RND efflux transporters in Burkholderia cenocepacia. PLoS One 6(4):e18902. http://dx.doi.org/10.1371/journal.pone.0018902.
15. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171-1175. http://dx.doi.org/10.1038/nature03912.
16. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 161(4 Part 1):1206-1212.
17. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310. http://dx.doi.org/10.1038/nature02122.
18. Gupta K, Marques CN, Petrova OE, Sauer K. 2013. Antimicrobial tolerance of Pseudomonas aeruginosa biofilms is activated during an early developmental stage and requires the two-component hybrid SagS. J Bacteriol 195:4975-4987. http://dx.doi.org/10.1128/JB.00732-13.
19. Bjarnsholt T, Ciofu O, Molin S, Givskov M, Hoiby N. 2013. Applying insights from biofilm biology to drug development - can a new approach be developed? Nat Rev Drug Discov 12:791-808. http://dx.doi.org/10.1038/nrd4000.
20. Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, Angyalosi G. 2011. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 46:230-238. http://dx.doi.org/10.1002/ppul.21356.
21. Staudinger BJ, Muller JF, Halldorsson S, Boles B, Angermeyer A, Nguyen D, Rosen H, Baldursson O, Gottfreethsson M, Guethmundsson GH, Singh PK. 2014. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 189:812-824. http://dx.doi.org/10.1164/rccm.201312-2142OC.
22. Van Acker H, Sass A, Bazzini S, De Roy K, Udine C, Messiaen T, Riccardi G, Boon N, Nelis HJ, Mahenthiralingam E, Coenye T. 2013. Biofilm-grown Burkholderia cepacia complex cells survive antibiotic treatment by avoiding production of reactive oxygen species. PLoS One 8(3):e58943. http://dx.doi.org/10.1371/journal.pone.0058943.
23. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340:23-30.
24. Messiaen AS, Forier K, Nelis H, Braeckmans K, Coenye T. 2013. Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms. PLoS One 8(11):e79220. http://dx.doi.org/10.1371/journal.pone.0079220.
25. Messiaen AS, Nelis H, Coenye T. 2014. Investigating the role of matrix components in protection of Burkholderia cepacia complex biofilms against tobramycin. J Cyst Fibros 13:56-62. http://dx.doi.org/10.1016/j.jcf.2013.07.004.
26. Bjarnsholt T, Alhede M, Eickhardt-Sorensen SR, Moser C, Kuhl M, Jensen PO, Hoiby N. 2013. The in vivo biofilm. Trends Microbiol 21:466-474. http://dx.doi.org/10.1016/j.tim.2013.06.002.
27. Caceres SM, Malcolm KC, Taylor-Cousar JL, Nichols DP, Saavedra MT, Bratton DL, Moskowitz SM, Burns JL, Nick JA. 2014. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob Agents Chemother 58:6851-6860. http://dx.doi.org/10.1128/AAC.03514-14.
28. Chatzimoschou A, Simitsopoulou M, Antachopoulos C, Walsh TJ, Roilides E. 2015. Antipseudomonal agents exhibit differential pharmacodynamic interactions with human polymorphonuclear leukocytes against established biofilms of Pseudomonas aeruginosa. Antimicrob Agents Chemother 59:2198-2205. http://dx.doi.org/10.1128/AAC.04934-14.